
March 12 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIALS THAT SHOW THE INVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN OF DORAVIRINE/ISLATRAVIR (DOR/ISL) MAINTAINED HIV-1 VIRAL SUPPRESSION AT WEEK 48
MERCK & CO INC - DOR/ISL SHOWS NON-INFERIORITY AND SIMILAR SAFETY PROFILE TO COMPARATORS
MERCK & CO INC - DOR/ISL MEETS PRIMARY EFFICACY AND SAFETY OBJECTIVES AT WEEK 48
MERCK & CO INC - PLANS TO BEGIN SUBMITTING APPLICATIONS FOR MARKETING AUTHORIZATION TO REGULATORY AGENCIES BY MID-2025